Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Ductal Carcinoma In Situ (DCIS) Clinical Trials

A listing of Ductal Carcinoma In Situ (DCIS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (63) clinical trials

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

Currently, the rate of ipsilateral breast tumor recurrence (IBTR) after breast- conserving surgery and radiotherapy remains at 10% at 10 years to 15% at 20 years, respectively. IBTR is an independent predictor of poor survival with a 3 to 4.6 increased risk of cancer-related death. In a heterogeneous population, local ...

Phase

Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.

Phase

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

This is a prospective non-randomised open-label study of exemestane in post-menopausal, hormone receptor positive advanced breast cancer patients, with pre-specified analysis of exemestane pharmacokinetics and pharmacodynamics according to UGT2B17 genotype (UGT2B172/2 versus those with at least one wild-type allele). A total of 110 patients will be enrolled over a period ...

Phase N/A

Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer

Breast cancer outcomes and cosmesis may differ by race. Limited but controversial data suggests that African-American women have worse cosmetic outcomes with hypofractionated irradiation than with conventional breast conservation. A growing body of data also suggests that African-American women have diminished oncologic outcomes when compared to Caucasian women in the ...

Phase N/A

Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients

This is a pilot study that investigate efficacy and safety of Sipjeondaebo-tang on fatigue of patients with breast carcinoma receiving chemotherapy.

Phase N/A

Axillary Reverse Mapping (ARM) Technique

Lymphedema is a major chronic morbidity that occurs in patients undergoing treatment for breast cancer (BC). Surgery for BC includes axillary surgery with either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Lymphedema occurs due to removal or disruption of lymphatic drainage of the arm that overlaps ...

Phase N/A

Trial Comparing Prone and Supine Intensity-modulated Radiotherapy (IMRT) After Breast-conserving Surgery in Patients With Large Breast Volume at High Risk for Skin Toxicity and Fibrosis

84 patients with a cup size C or more will be randomized to receive intensity-modulated radiotherapy in supine or prone position.

Phase N/A

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) ...

Phase

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

PRIMARY OBJECTIVES: I. To evaluate 24 month breast photographic cosmetic scores with 9 fraction radiation compared to standard hypofractionation. SECONDARY OBJECTIVES: I. To evaluate Breast-Q patient reported outcomes (PROs) compared to historical control in breast conservation. II. To evaluate the incidence of acute and late radiation complications, based on Common ...

Phase

Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.

Phase